Literature DB >> 20430330

Safety considerations in the use of botulinum toxins in children with cerebral palsy.

Susan D Apkon1, Danielle Cassidy.   

Abstract

The use of botulinum toxins to decrease spasticity in children with cerebral palsy has become standard of care during the past decade. In 2008 reports of severe adverse events, including death, were reported in children who received injections of these medications. The following discussion focuses on the background of these reports, the response of the U.S. Food and Drug Administration, as well as the safety profile and pharmacokinetics of botulinum toxins. Finally, the authors will offer their perspective on the safe use of botulinum toxins. Copyright 2010 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430330     DOI: 10.1016/j.pmrj.2010.02.006

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  3 in total

Review 1.  Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.

Authors:  Mohammad Alimohammadi; Anna Rostedt Punga
Journal:  Toxins (Basel)       Date:  2017-10-30       Impact factor: 4.546

2.  Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins.

Authors:  Toshiaki Takeuchi; Tsuyoshi Okuno; Ai Miyashiro; Tomoko Kohda; Ryosuke Miyamoto; Yuishin Izumi; Shunji Kozaki; Ryuji Kaji
Journal:  Toxins (Basel)       Date:  2021-11-22       Impact factor: 4.546

3.  Focal treatment of spasticity using botulinum toxin A in cerebral palsy cases of GMFCS level V: evaluation of adverse effects.

Authors:  Ana Paula Tedesco; Juliana Saccol Martins; Renata D'Agostini Nicolini-Panisson
Journal:  Rev Bras Ortop       Date:  2014-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.